Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Study Details
Study Description
Brief Summary
Assess the safety and tumor response of utilizing an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine given in combination with standard of care (SoC) checkpoint inhibitors (CPI) in patients with stage IV melanoma with measurable disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
Metastatic melanoma patients eligible for (or currently on) CPI therapy per SoC will be identified and screened for inclusion/exclusion criteria. Eligible patients will be counseled and consented for tissue procurement. They will undergo excisional or core needle biopsy as clinically indicated and this tissue will be shipped in liquid nitrogen shippers through FedEx to our central facility in Greenville, SC.The tumor will be stored frozen until vaccine preparation. Vaccine development requires 48 hours for preparation. Upon verification that adequate tissue was obtained, these patients will then be counseled and consented for participation in the trial.
The patients who qualify for participation in this trial will continue their treatment of CPI. Once consented, patients will receive a single injection of Neupogen (G-CSF) 300 μg SQ 24-48 hrs prior to having 70 mL of blood collected and sent to our central facility for DC isolation and preparation. Those who cannot tolerate Neupogen or refuse it will have 120 mL of blood drawn and sent. Additional blood may be drawn if additional vaccine doses need to be made or re-made for any reason. Vaccines will be prepared by producing TL through freeze/thaw cycling and then loaded into pre-prepared YCWP. The TL-loaded YCWP will be introduced to the DC for phagocytosis thus creating the TLPLDC vaccine, which will be frozen in single dose vials. Each vial will contain 1 x 106 TLPLDC and will be labeled with the patient's unique study number.
The frozen autologous TLPLDC will be sent back to the site with a total of 6 single dose vials after the vaccine has completed QA/QC testing and lot-release (usually 3 weeks). The primary vaccination series will include monthly inoculations at 0, 1, 2, 3 months followed by boosters at 6 and 9 months in the same lymph node draining area (preferably the anterior thigh). Once received, the first inoculation should occur within 4 weeks.
Safety data will be collected on local and systemic toxicities and graded and reported per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Patients will follow-up at their respective sites for evaluation of metastatic disease per SoC. They will under imaging, CT/PET-CT, to meet Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 and iRECIST to monitor disease.
Blood (50 mL) will be collected from all patients prior to each inoculation and at 12 months from enrollment for a total of 7 time points or a total of 350 mL of blood over 1 year. The collected blood will be sent to our central facility for immunologic testing of T-cell responses.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: No clinical response No clinical response (PD de novo) after a minimum of 3 months on CPI monotherapy |
Drug: TLPLDC Vaccine
Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
|
| Active Comparator: Develop PD Develop PD after initial clinical response to CPI monotherapy |
Drug: TLPLDC Vaccine
Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
|
| Active Comparator: Stable Disease Stable disease for at least 6 months on CPI monotherapy |
Drug: TLPLDC Vaccine
Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
|
Outcome Measures
Primary Outcome Measures
- Graded Standard Local and Systemic Toxicities (using CTCAE graded toxicity scale) months [12 months (1 year)]
Safety of adding the TLPLDC vaccine to SoC CPI monotherapy
Secondary Outcome Measures
- Tumor Response to Treatment Using Response Evaluation Criteria in Solid Tumors (RECIST) criteria [12 months (1 year)]
RECIST criteria is used for assessing tumor response in the addition of TLPLDC vaccine
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years or older
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix A)
-
Metastatic melanoma eligible for standard of care CPI therapy (treating physician's choice) with measurable disease.
-
Approximately 1 cm3 preferred but 1 mg minimum of accessible and dispensable tumor (minimum of 3 passes with a core needle)
-
Able to tolerate CPI treatment regimen
-
Adequate organ function as determined by the following laboratory values:
-
ANC ≥ 1,000/μL
-
Platelets ≥ 75,000/μL
-
Hgb ≥ 9 g/dL
-
Creatinine ≤ 1.5 x upper limit of normal (ULN) or Creatinine clearance ≥ 50% of lower limit of normal (LLN)
-
Total bilirubin ≤ 1.5 ULN
-
ALT and AST ≤ 1.5 ULN
-
For women of child-bearing potential, agreement to use adequate birth control (abstinence, hysterectomy, bilateral oophorectomy, bilateral tubal ligation, oral contraception, IUD, or use of condoms or diaphragms)
Exclusion Criteria:
-
Inability to tolerate CPI therapy
-
Rapidly progressing multi-focal metastatic melanoma
-
Insufficient tumor available to produce vaccine
-
ECOG >2 performance status (Appendix A)
-
Immune deficiency disease or known history of HIV, HBV, HCV
-
Receiving immunosuppressive therapy including chronic steroids (except physiologic maintenance doses), methotrexate, or other known immunosuppressive agents
-
Pregnancy (assessed by urine HCG)
-
Breast feeding
-
Active pulmonary disease requiring medication to include multiple inhalers (>2 inhalers and one containing steroids)
-
Involved in other experimental protocols (except with permission of the other study PI)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Alabama Birmingham Comprehensive Cancer Center | Birmingham | Alabama | United States | 35243 |
| 2 | John Wayne Cancer Institute/Providence Saint John's Health Center | Santa Monica | California | United States | 90404 |
| 3 | Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | United States | 33140 |
| 4 | Northside Hospital | Atlanta | Georgia | United States | 30342 |
| 5 | University of Cincinnati Cancer Institute | Cincinnati | Ohio | United States | 45267 |
| 6 | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | United States | 19107 |
| 7 | Providence Regional Medical Center | Everett | Washington | United States | 98201 |
Sponsors and Collaborators
- Cancer Insight, LLC
- Elios Therapeutics, LLC
Investigators
- Study Director: George Peoples, MD, Cancer Insight, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20152397